Track record · closed signal

Gilead Sciences Inc (GILD) — closed signal from April 20, 2026

Partial Published before the outcome was known, scored automatically when the window closed on July 19, 2026.

Predicted vs. what happened

GILD price · publication thesis → realized outcomesplit-adjusted
$136.27 Published $151.63 Target $134.28 Window close $140.61 Peak
$132.26 – $137.19Entry zone — fair-value band
$136.27Published — price the day we called it
$151.63Target — the price the thesis aimed for
$140.61Peak — highest point inside the window, not a realized return
$134.28Window close — end-of-window price, context only

What happened

Partial

Reached 27% of the predicted growth at its peak, without hitting the target.

Peak price
$140.61
peak on July 17, 2026 — not a realized return
Peak gain
+3.2%
peak, from the publication price
Window close
$134.28
end-of-window price, context only
Days to target
Window
April 20, 2026 – July 19, 2026

The thesis — published April 20, 2026

Predicted growth
+12%
over the measurement window
Target price
$151.63
the price the thesis aimed for
Entry zone
$132.26 – $137.19
the fair-value band we waited for
Price at publication
$136.27
published April 20, 2026
Confidence
76%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Gilead mixes steady profits with near-term opportunities in cancer drugs and HIV. Recent updates on expanded cancer programs, efforts to broaden access to lenacapavir, and a raised price target make the short-term picture more positive. The stock is rebounding from weakness and the outlook does not rely on a broad biotech rally.

Primary drivers

  • New cancer program expansion widens future drug options
  • Efforts to broaden lenacapavir access strengthen HIV story
  • Strong profits help the stock weather downturns
  • Lowered share levels make recovery more plausible

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.